Zanamivir hydrate | CAS# 551942-41-7 | xxxx

MedKoo Cat#: 581075 | Name: Zanamivir hydrate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Zanamivir hydrate is neuraminidase inhibitors (NAIs) and is used worldwide for treatment and prophylaxis of influenza caused by influenza A and B viruses.

Chemical Structure

Zanamivir hydrate

CAS#551942-41-7 (hydrate)

Theoretical Analysis

MedKoo Cat#: 581075

Name: Zanamivir hydrate

CAS#: 551942-41-7 (hydrate)

Chemical Formula: C12H22N4O8

Exact Mass: 350.1438

Molecular Weight: 350.33

Elemental Analysis: C, 41.14; H, 6.33; N, 15.99; O, 36.53

Price and Availability

Size	Price	Availability	Quantity
250mg	USD 400.00	2 Weeks
1g	USD 850.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

139110-80-8 (free base) 551942-41-7 (hydrate)

Synonym

Zanamivir hydrate; D01937; J1.917.534K;

IUPAC/Chemical Name

(+)-(4S,5R,6R)-5-Acetylamino-4-guanidino-6-((1R,2R)-1,2,3- trihydroxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid hydrate

InChi Key

OELRRAURPSTFEX-VCFRRRQNSA-N

InChi Code

InChI=1S/C12H20N4O7.H2O/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17;/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16);1H2/t5-,6+,8+,9+,10+;/m0./s1

SMILES Code

O=C(C1=C[C@H](NC(N)=N)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O1)O.[H]O[H]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 350.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014 Apr 9;348:g2547. doi: 10.1136/bmj.g2547. Review. PubMed PMID: 24811412; PubMed Central PMCID: PMC3981976. 2: Pizzorno A, Abed Y, Rhéaume C, Boivin G. Oseltamivir-zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses. Antiviral Res. 2014 May;105:54-8. doi: 10.1016/j.antiviral.2014.02.017. Epub 2014 Feb 28. PubMed PMID: 24583158. 3: Chan-Tack KM, Kim C, Moruf A, Birnkrant DB. Clinical experience with intravenous zanamivir under an Emergency IND program in the United States (2011-2014). Antivir Ther. 2015;20(5):561-4. doi: 10.3851/IMP2944. Epub 2015 Feb 10. Review. PubMed PMID: 25667992. 4: Dunstan HJ, Mill AC, Stephens S, Yates LM, Thomas SH. Pregnancy outcome following maternal use of zanamivir or oseltamivir during the 2009 influenza A/H1N1 pandemic: a national prospective surveillance study. BJOG. 2014 Jun;121(7):901-6. doi: 10.1111/1471-0528.12640. Epub 2014 Mar 7. PubMed PMID: 24602087. 5: Tarbet EB, Hamilton S, Vollmer AH, Luttick A, Ng WC, Pryor M, Hurst BL, Crawford S, Smee DF, Tucker SP. A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses. J Antimicrob Chemother. 2014 Aug;69(8):2164-74. doi: 10.1093/jac/dku127. Epub 2014 Apr 28. PubMed PMID: 24777908; PubMed Central PMCID: PMC4100710. 6: Yang Y, Yang Z, Ren Y, Mei X. Effects of formulation and operating variables on zanamivir dry powder inhalation characteristics and aerosolization performance. Drug Deliv. 2014 Sep;21(6):480-6. doi: 10.3109/10717544.2014.883113. Epub 2014 Feb 4. PubMed PMID: 24491208. 7: Sato M, Honzumi K, Sato T, Hashimoto K, Watanabe M, Miyazaki K, Kawasaki Y, Hosoya M. Sequential influenza B viral load and susceptibility in children treated with oseltamivir and zanamivir. Pediatr Infect Dis J. 2014 Jul;33(7):e168-72. doi: 10.1097/INF.0000000000000266. PubMed PMID: 24445826. 8: Lou Y, Gan J, Peppercorn A, Gould E, Weller S, Piscitelli SC, Patel P. Effect of intravenous zanamivir on cardiac repolarization. Pharmacotherapy. 2013 Jul;33(7):701-9. doi: 10.1002/phar.1261. Epub 2013 Apr 3. PubMed PMID: 23553534. 9: Marty FM, Man CY, van der Horst C, Francois B, Garot D, Mánez R, Thamlikitkul V, Lorente JA, Alvarez-Lerma F, Brealey D, Zhao HH, Weller S, Yates PJ, Peppercorn AF. Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study. J Infect Dis. 2014 Feb 15;209(4):542-50. doi: 10.1093/infdis/jit467. Epub 2013 Aug 27. PubMed PMID: 23983212; PubMed Central PMCID: PMC4047294. 10: Tian J, Zhong J, Li Y, Ma D. Organocatalytic and scalable synthesis of the anti-influenza drugs zanamivir, laninamivir, and CS-8958. Angew Chem Int Ed Engl. 2014 Dec 8;53(50):13885-8. doi: 10.1002/anie.201408138. Epub 2014 Oct 14. PubMed PMID: 25314609. 11: Shanmugam S. Zanamivir oral delivery: possibilities revisited. Ther Deliv. 2015;6(4):403-5. doi: 10.4155/tde.15.9. PubMed PMID: 25996038. 12: Weight AK, Belser JA, Tumpey TM, Chen J, Klibanov AM. Zanamivir conjugated to poly-L-glutamine is much more active against influenza viruses in mice and ferrets than the drug itself. Pharm Res. 2014 Feb;31(2):466-74. doi: 10.1007/s11095-013-1175-4. Epub 2013 Sep 25. PubMed PMID: 24065587; PubMed Central PMCID: PMC3964776. 13: Shi LL, Cao Y, Zhu XY, Cui JH, Cao QR. Optimization of process variables of zanamivir-loaded solid lipid nanoparticles and the prediction of their cellular transport in Caco-2 cell model. Int J Pharm. 2015 Jan 15;478(1):60-9. doi: 10.1016/j.ijpharm.2014.11.017. Epub 2014 Nov 12. PubMed PMID: 25448568. 14: Weller S, Jones LS, Lou Y, Peppercorn A, Ng-Cashin J. Pharmacokinetics of zanamivir following intravenous administration to subjects with and without renal impairment. Antimicrob Agents Chemother. 2013 Jul;57(7):2967-71. doi: 10.1128/AAC.02330-12. Epub 2013 Apr 15. PubMed PMID: 23587959; PubMed Central PMCID: PMC3697365. 15: Zonja B, Gonçalves C, Pérez S, Delgado A, Petrovic M, Alpendurada MF, Barceló D. Evaluation of the phototransformation of the antiviral zanamivir in surface waters through identification of transformation products. J Hazard Mater. 2014 Jan 30;265:296-304. doi: 10.1016/j.jhazmat.2013.10.008. Epub 2013 Oct 24. PubMed PMID: 24211180. 16: Coleman BL, Fadel SA, Drews SJ, Hatchette TF, McGeer AJ. Zanamivir versus trivalent split virus influenza vaccine: a pilot randomized trial. Influenza Other Respir Viruses. 2015 Mar;9(2):78-84. doi: 10.1111/irv.12301. Epub 2015 Jan 4. PubMed PMID: 25557838; PubMed Central PMCID: PMC4353320. 17: Schade D, Kotthaus J, Riebling L, Kotthaus J, Müller-Fielitz H, Raasch W, Hoffmann A, Schmidtke M, Clement B. Zanamivir Amidoxime- and N-Hydroxyguanidine-Based Prodrug Approaches to Tackle Poor Oral Bioavailability. J Pharm Sci. 2015 Sep;104(9):3208-19. doi: 10.1002/jps.24508. Epub 2015 Jun 2. PubMed PMID: 26037932. 18: Morokutti-Kurz M, König-Schuster M, Koller C, Graf C, Graf P, Kirchoff N, Reutterer B, Seifert JM, Unger H, Grassauer A, Prieschl-Grassauer E, Nakowitsch S. The Intranasal Application of Zanamivir and Carrageenan Is Synergistically Active against Influenza A Virus in the Murine Model. PLoS One. 2015 Jun 8;10(6):e0128794. doi: 10.1371/journal.pone.0128794. eCollection 2015. PubMed PMID: 26053018; PubMed Central PMCID: PMC4459876. 19: Shida Y, Hara K, Nohda S, Soutome T, Hirama T. The pharmacokinetic and safety profiles of zanamivir after single and repeat intravenous administration in healthy Japanese males. J Clin Pharm Ther. 2013 Jun;38(3):236-40. doi: 10.1111/jcpt.12056. Epub 2013 Mar 14. PubMed PMID: 23489210. 20: Thai KM, Le DP, Tran NV, Nguyen TT, Tran TD, Le MT. Computational assay of Zanamivir binding affinity with original and mutant influenza neuraminidase 9 using molecular docking. J Theor Biol. 2015 Nov 21;385:31-9. doi: 10.1016/j.jtbi.2015.08.019. Epub 2015 Sep 1. PubMed PMID: 26341387.